The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global IgA Nephropathy Treatment Market Research Report 2025
Synopsis
Currently, there are two main methods for the treatment of IgA nephropathy, one is conservative therapy and the other is immunosuppressive therapy.
Global IgA Nephropathy Treatment market is projected to reach US$ 50 million in 2029, increasing from US$ 15 million in 2022, with the CAGR of 19.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole IgA Nephropathy Treatment market research.
Clearances and approval of new drugs, as well as major campaigns establishments for increasing awareness among people regarding IgA Nephropathy disease and health checkups, will have a positive impact on the market growth. For instance, US Food and Drug Administration, in September 2022, provided clearance to the Investigational New Drug (IND) Application of Eldon Pharmaceutical for assessment of tegoprubart to treat IgA Nephropathy.
Growing health consciousness coupled with high per capita disposable income is significantly contributing to the market growth. According to a nationwide study published in the Journal of the American Society of Nephrology, the incidence rate of IgA nephropathy (IgAN) is estimated to be 2-10 per 100,000 individuals a year.
The USA is at high risk for such diseases due to the growing number of chronic diseases and a sedentary lifestyle. According to the US National Institute of Diabetes and Digestive and Kidney Disease, Department of Health and Human Services, Chronic kidney disease (CKD) affects more than one in seven US Adults. As per the report by the Centers for Disease Control and Prevention (CDC) on chronic kidney disease in the United States, in 2021, there are about 37 million people affected by chronic kidney diseases.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global IgA Nephropathy Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AstraZeneca
Johnson & Johnson Private Limited
Cipla Inc.
Hikma Pharmaceuticals PLC
Zydus Cadila
LEO Pharma A/S
Fresenius Kabi AG
Accord Healthcare
Abbott
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Novartis AG
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma
Lupin
Alembic Pharmaceuticals Limited
Apotex Inc
Eldon Pharmaceutical
Segment by Type
Corticosteroids
Immunosuppressant
ACE and ARB Inhibitors
Segment by Application
Hospital
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The IgA Nephropathy Treatment report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Currently, there are two main methods for the treatment of IgA nephropathy, one is conservative therapy and the other is immunosuppressive therapy.
Global IgA Nephropathy Treatment market is projected to reach US$ 50 million in 2029, increasing from US$ 15 million in 2022, with the CAGR of 19.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole IgA Nephropathy Treatment market research.
Clearances and approval of new drugs, as well as major campaigns establishments for increasing awareness among people regarding IgA Nephropathy disease and health checkups, will have a positive impact on the market growth. For instance, US Food and Drug Administration, in September 2022, provided clearance to the Investigational New Drug (IND) Application of Eldon Pharmaceutical for assessment of tegoprubart to treat IgA Nephropathy.
Growing health consciousness coupled with high per capita disposable income is significantly contributing to the market growth. According to a nationwide study published in the Journal of the American Society of Nephrology, the incidence rate of IgA nephropathy (IgAN) is estimated to be 2-10 per 100,000 individuals a year.
The USA is at high risk for such diseases due to the growing number of chronic diseases and a sedentary lifestyle. According to the US National Institute of Diabetes and Digestive and Kidney Disease, Department of Health and Human Services, Chronic kidney disease (CKD) affects more than one in seven US Adults. As per the report by the Centers for Disease Control and Prevention (CDC) on chronic kidney disease in the United States, in 2021, there are about 37 million people affected by chronic kidney diseases.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global IgA Nephropathy Treatment market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AstraZeneca
Johnson & Johnson Private Limited
Cipla Inc.
Hikma Pharmaceuticals PLC
Zydus Cadila
LEO Pharma A/S
Fresenius Kabi AG
Accord Healthcare
Abbott
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Novartis AG
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma
Lupin
Alembic Pharmaceuticals Limited
Apotex Inc
Eldon Pharmaceutical
Segment by Type
Corticosteroids
Immunosuppressant
ACE and ARB Inhibitors
Segment by Application
Hospital
Pharmacy
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The IgA Nephropathy Treatment report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 IgA Nephropathy Treatment Market Overview
1.1 Product Overview and Scope of IgA Nephropathy Treatment
1.2 IgA Nephropathy Treatment Segment by Type
1.2.1 Global IgA Nephropathy Treatment Market Value Comparison by Type (2023-2029)
1.2.2 Corticosteroids
1.2.3 Immunosuppressant
1.2.4 ACE and ARB Inhibitors
1.3 IgA Nephropathy Treatment Segment by Application
1.3.1 Global IgA Nephropathy Treatment Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global IgA Nephropathy Treatment Market Size Estimates and Forecasts
1.4.1 Global IgA Nephropathy Treatment Revenue 2018-2029
1.4.2 Global IgA Nephropathy Treatment Sales 2018-2029
1.4.3 Global IgA Nephropathy Treatment Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 IgA Nephropathy Treatment Market Competition by Manufacturers
2.1 Global IgA Nephropathy Treatment Sales Market Share by Manufacturers (2018-2023)
2.2 Global IgA Nephropathy Treatment Revenue Market Share by Manufacturers (2018-2023)
2.3 Global IgA Nephropathy Treatment Average Price by Manufacturers (2018-2023)
2.4 Global IgA Nephropathy Treatment Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of IgA Nephropathy Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of IgA Nephropathy Treatment, Product Type & Application
2.7 IgA Nephropathy Treatment Market Competitive Situation and Trends
2.7.1 IgA Nephropathy Treatment Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest IgA Nephropathy Treatment Players Market Share by Revenue
2.7.3 Global IgA Nephropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 IgA Nephropathy Treatment Retrospective Market Scenario by Region
3.1 Global IgA Nephropathy Treatment Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global IgA Nephropathy Treatment Global IgA Nephropathy Treatment Sales by Region: 2018-2029
3.2.1 Global IgA Nephropathy Treatment Sales by Region: 2018-2023
3.2.2 Global IgA Nephropathy Treatment Sales by Region: 2024-2029
3.3 Global IgA Nephropathy Treatment Global IgA Nephropathy Treatment Revenue by Region: 2018-2029
3.3.1 Global IgA Nephropathy Treatment Revenue by Region: 2018-2023
3.3.2 Global IgA Nephropathy Treatment Revenue by Region: 2024-2029
3.4 North America IgA Nephropathy Treatment Market Facts & Figures by Country
3.4.1 North America IgA Nephropathy Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America IgA Nephropathy Treatment Sales by Country (2018-2029)
3.4.3 North America IgA Nephropathy Treatment Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe IgA Nephropathy Treatment Market Facts & Figures by Country
3.5.1 Europe IgA Nephropathy Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe IgA Nephropathy Treatment Sales by Country (2018-2029)
3.5.3 Europe IgA Nephropathy Treatment Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific IgA Nephropathy Treatment Market Facts & Figures by Country
3.6.1 Asia Pacific IgA Nephropathy Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific IgA Nephropathy Treatment Sales by Country (2018-2029)
3.6.3 Asia Pacific IgA Nephropathy Treatment Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America IgA Nephropathy Treatment Market Facts & Figures by Country
3.7.1 Latin America IgA Nephropathy Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America IgA Nephropathy Treatment Sales by Country (2018-2029)
3.7.3 Latin America IgA Nephropathy Treatment Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa IgA Nephropathy Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa IgA Nephropathy Treatment Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa IgA Nephropathy Treatment Sales by Country (2018-2029)
3.8.3 Middle East and Africa IgA Nephropathy Treatment Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global IgA Nephropathy Treatment Sales by Type (2018-2029)
4.1.1 Global IgA Nephropathy Treatment Sales by Type (2018-2023)
4.1.2 Global IgA Nephropathy Treatment Sales by Type (2024-2029)
4.1.3 Global IgA Nephropathy Treatment Sales Market Share by Type (2018-2029)
4.2 Global IgA Nephropathy Treatment Revenue by Type (2018-2029)
4.2.1 Global IgA Nephropathy Treatment Revenue by Type (2018-2023)
4.2.2 Global IgA Nephropathy Treatment Revenue by Type (2024-2029)
4.2.3 Global IgA Nephropathy Treatment Revenue Market Share by Type (2018-2029)
4.3 Global IgA Nephropathy Treatment Price by Type (2018-2029)
5 Segment by Application
5.1 Global IgA Nephropathy Treatment Sales by Application (2018-2029)
5.1.1 Global IgA Nephropathy Treatment Sales by Application (2018-2023)
5.1.2 Global IgA Nephropathy Treatment Sales by Application (2024-2029)
5.1.3 Global IgA Nephropathy Treatment Sales Market Share by Application (2018-2029)
5.2 Global IgA Nephropathy Treatment Revenue by Application (2018-2029)
5.2.1 Global IgA Nephropathy Treatment Revenue by Application (2018-2023)
5.2.2 Global IgA Nephropathy Treatment Revenue by Application (2024-2029)
5.2.3 Global IgA Nephropathy Treatment Revenue Market Share by Application (2018-2029)
5.3 Global IgA Nephropathy Treatment Price by Application (2018-2029)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Corporation Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.1.4 AstraZeneca IgA Nephropathy Treatment Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Johnson & Johnson Private Limited
6.2.1 Johnson & Johnson Private Limited Corporation Information
6.2.2 Johnson & Johnson Private Limited Description and Business Overview
6.2.3 Johnson & Johnson Private Limited IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Johnson & Johnson Private Limited IgA Nephropathy Treatment Product Portfolio
6.2.5 Johnson & Johnson Private Limited Recent Developments/Updates
6.3 Cipla Inc.
6.3.1 Cipla Inc. Corporation Information
6.3.2 Cipla Inc. Description and Business Overview
6.3.3 Cipla Inc. IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Cipla Inc. IgA Nephropathy Treatment Product Portfolio
6.3.5 Cipla Inc. Recent Developments/Updates
6.4 Hikma Pharmaceuticals PLC
6.4.1 Hikma Pharmaceuticals PLC Corporation Information
6.4.2 Hikma Pharmaceuticals PLC Description and Business Overview
6.4.3 Hikma Pharmaceuticals PLC IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Hikma Pharmaceuticals PLC IgA Nephropathy Treatment Product Portfolio
6.4.5 Hikma Pharmaceuticals PLC Recent Developments/Updates
6.5 Zydus Cadila
6.5.1 Zydus Cadila Corporation Information
6.5.2 Zydus Cadila Description and Business Overview
6.5.3 Zydus Cadila IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Zydus Cadila IgA Nephropathy Treatment Product Portfolio
6.5.5 Zydus Cadila Recent Developments/Updates
6.6 LEO Pharma A/S
6.6.1 LEO Pharma A/S Corporation Information
6.6.2 LEO Pharma A/S Description and Business Overview
6.6.3 LEO Pharma A/S IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.6.4 LEO Pharma A/S IgA Nephropathy Treatment Product Portfolio
6.6.5 LEO Pharma A/S Recent Developments/Updates
6.7 Fresenius Kabi AG
6.6.1 Fresenius Kabi AG Corporation Information
6.6.2 Fresenius Kabi AG Description and Business Overview
6.6.3 Fresenius Kabi AG IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Fresenius Kabi AG IgA Nephropathy Treatment Product Portfolio
6.7.5 Fresenius Kabi AG Recent Developments/Updates
6.8 Accord Healthcare
6.8.1 Accord Healthcare Corporation Information
6.8.2 Accord Healthcare Description and Business Overview
6.8.3 Accord Healthcare IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Accord Healthcare IgA Nephropathy Treatment Product Portfolio
6.8.5 Accord Healthcare Recent Developments/Updates
6.9 Abbott
6.9.1 Abbott Corporation Information
6.9.2 Abbott Description and Business Overview
6.9.3 Abbott IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Abbott IgA Nephropathy Treatment Product Portfolio
6.9.5 Abbott Recent Developments/Updates
6.10 F. Hoffmann-La Roche Ltd.
6.10.1 F. Hoffmann-La Roche Ltd. Corporation Information
6.10.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
6.10.3 F. Hoffmann-La Roche Ltd. IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.10.4 F. Hoffmann-La Roche Ltd. IgA Nephropathy Treatment Product Portfolio
6.10.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
6.11 Mylan N.V.
6.11.1 Mylan N.V. Corporation Information
6.11.2 Mylan N.V. IgA Nephropathy Treatment Description and Business Overview
6.11.3 Mylan N.V. IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Mylan N.V. IgA Nephropathy Treatment Product Portfolio
6.11.5 Mylan N.V. Recent Developments/Updates
6.12 Teva Pharmaceutical Industries Ltd.
6.12.1 Teva Pharmaceutical Industries Ltd. Corporation Information
6.12.2 Teva Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Description and Business Overview
6.12.3 Teva Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Teva Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Product Portfolio
6.12.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
6.13 Sanofi
6.13.1 Sanofi Corporation Information
6.13.2 Sanofi IgA Nephropathy Treatment Description and Business Overview
6.13.3 Sanofi IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Sanofi IgA Nephropathy Treatment Product Portfolio
6.13.5 Sanofi Recent Developments/Updates
6.14 Novartis AG
6.14.1 Novartis AG Corporation Information
6.14.2 Novartis AG IgA Nephropathy Treatment Description and Business Overview
6.14.3 Novartis AG IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Novartis AG IgA Nephropathy Treatment Product Portfolio
6.14.5 Novartis AG Recent Developments/Updates
6.15 Sun Pharmaceutical Industries Ltd.
6.15.1 Sun Pharmaceutical Industries Ltd. Corporation Information
6.15.2 Sun Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Description and Business Overview
6.15.3 Sun Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Sun Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Product Portfolio
6.15.5 Sun Pharmaceutical Industries Ltd. Recent Developments/Updates
6.16 Aurobindo Pharma
6.16.1 Aurobindo Pharma Corporation Information
6.16.2 Aurobindo Pharma IgA Nephropathy Treatment Description and Business Overview
6.16.3 Aurobindo Pharma IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Aurobindo Pharma IgA Nephropathy Treatment Product Portfolio
6.16.5 Aurobindo Pharma Recent Developments/Updates
6.17 Lupin
6.17.1 Lupin Corporation Information
6.17.2 Lupin IgA Nephropathy Treatment Description and Business Overview
6.17.3 Lupin IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Lupin IgA Nephropathy Treatment Product Portfolio
6.17.5 Lupin Recent Developments/Updates
6.18 Alembic Pharmaceuticals Limited
6.18.1 Alembic Pharmaceuticals Limited Corporation Information
6.18.2 Alembic Pharmaceuticals Limited IgA Nephropathy Treatment Description and Business Overview
6.18.3 Alembic Pharmaceuticals Limited IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Alembic Pharmaceuticals Limited IgA Nephropathy Treatment Product Portfolio
6.18.5 Alembic Pharmaceuticals Limited Recent Developments/Updates
6.19 Apotex Inc
6.19.1 Apotex Inc Corporation Information
6.19.2 Apotex Inc IgA Nephropathy Treatment Description and Business Overview
6.19.3 Apotex Inc IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Apotex Inc IgA Nephropathy Treatment Product Portfolio
6.19.5 Apotex Inc Recent Developments/Updates
6.20 Eldon Pharmaceutical
6.20.1 Eldon Pharmaceutical Corporation Information
6.20.2 Eldon Pharmaceutical IgA Nephropathy Treatment Description and Business Overview
6.20.3 Eldon Pharmaceutical IgA Nephropathy Treatment Sales, Revenue and Gross Margin (2018-2023)
6.20.4 Eldon Pharmaceutical IgA Nephropathy Treatment Product Portfolio
6.20.5 Eldon Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 IgA Nephropathy Treatment Industry Chain Analysis
7.2 IgA Nephropathy Treatment Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 IgA Nephropathy Treatment Production Mode & Process
7.4 IgA Nephropathy Treatment Sales and Marketing
7.4.1 IgA Nephropathy Treatment Sales Channels
7.4.2 IgA Nephropathy Treatment Distributors
7.5 IgA Nephropathy Treatment Customers
8 IgA Nephropathy Treatment Market Dynamics
8.1 IgA Nephropathy Treatment Industry Trends
8.2 IgA Nephropathy Treatment Market Drivers
8.3 IgA Nephropathy Treatment Market Challenges
8.4 IgA Nephropathy Treatment Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
